We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Humana Beat Q3 Earnings Estimates on Growing Premiums?
Read MoreHide Full Article
Key Takeaways
Humana is set to report Q3 2025 results on Nov. 5, with EPS estimated at $2.91 on $31.98B revenues.
Premiums are projected to rise 8.6% and service revenues 25.6%, driving expected top-line growth.
Higher costs and lower investment income may weigh on HUM's bottom line despite solid revenue gains.
Humana Inc. (HUM - Free Report) is set to report third-quarter 2025 results on Nov. 5, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $2.91 per shareon revenues of $31.98 billion.
The third-quarter earnings estimate has increased by a penny over the past 60 days. However, the bottom-line projection indicates a year-over-year decrease of 30.1%. Yet, the Zacks Consensus Estimate for quarterly revenues implies year-over-year growth of 9.1%.
Image Source: Zacks Investment Research
For full-year 2025, the Zacks Consensus Estimate for Humana’s revenues is pegged at $128.21 billion, implying a rise of 9.4% year over year. Also, the consensus mark for the current year EPS is pegged at $17.05, implying a gain of around 5.2% on a year-over-year basis.
HUM’s earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being 9.6%.
Our proven model predicts a likely earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is precisely the case here.
Humana has an Earnings ESP of +4.29% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for HUM’s third-quarter premiums indicates an 8.6% increase from the prior-year quarter’s reported figure, whereas our model predicts 8.2% growth. We expect total Medicare to witness nearly 6% growth in the quarter under review. Similarly, the consensus mark for service revenues signals a 25.6% increase from a year ago. These are expected to have positioned the company for an earnings beat in the third quarter.
However, the Zacks Consensus Estimate for operating income from the Insurance unit indicates a 1.9% decline from a year ago. The same for the CenterWell unit predicts a 2% decrease from the year-ago level.
Furthermore, the consensus estimate indicates that Humana’s investment income will see a 21% drop from the year-ago level. We expect total operating costs to increase 8.7% in the third quarter, pushing the figure above $31 billion. This is likely to have led to a year-over-year decline in the bottom line.
The consensus mark for the overall benefits expense ratio is pegged at 90.86% for the to-be-reported quarter, deteriorating from 89.9% a year ago. Also, the Zacks Consensus Estimate for insurance membership suggests a 7.1% year-over-year decline, whereas specialty membership is expected to grow 1.3%.
How Did Peers Perform?
Several healthcare companies, including Centene Corporation (CNC - Free Report) , Molina Healthcare, Inc. (MOH - Free Report) and Elevance Health, Inc. (ELV - Free Report) , have already reported their financial results for the September quarter of 2025. Here’s how they had performed:
Centene reported third-quarter 2025 adjusted earnings per share of 50 cents, which beat the Zacks Consensus Estimate of a loss of 21 cents. However, the bottom line fell from the year-ago profit of $1.62 per share.The results benefited from solid premium growth, fueled by expanding membership in the PDP and Commercial Marketplace businesses, along with overall growth in the Marketplace business. However, the upside was partly offset by Centene’s rising medical costs, declining service revenues and year-over-year membership falls in Medicaid and Medicare businesses.
Molina reported third-quarter 2025 adjusted EPS of $1.84, which missed the Zacks Consensus Estimate of $3.97. Also, the bottom line fell 69.4% from the year-ago period.The earnings were affected by higher medical care costs and general and administrative expenses. However, Molina’s rising premiums and rate hikes partially offset the negatives.
Elevance reported third-quarter 2025 adjusted EPS of $6.03, which surpassed the Zacks Consensus Estimate by 21.1%. Yet, the bottom line dropped 29.9% year over year. The results benefited from the back of strong growth in premiums, product revenues and net investment income. However, the upside was partly offset by a decline in Elevance’s overall medical membership due to Medicaid reverifications and an elevated expense level.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Humana Beat Q3 Earnings Estimates on Growing Premiums?
Key Takeaways
Humana Inc. (HUM - Free Report) is set to report third-quarter 2025 results on Nov. 5, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $2.91 per shareon revenues of $31.98 billion.
The third-quarter earnings estimate has increased by a penny over the past 60 days. However, the bottom-line projection indicates a year-over-year decrease of 30.1%. Yet, the Zacks Consensus Estimate for quarterly revenues implies year-over-year growth of 9.1%.
For full-year 2025, the Zacks Consensus Estimate for Humana’s revenues is pegged at $128.21 billion, implying a rise of 9.4% year over year. Also, the consensus mark for the current year EPS is pegged at $17.05, implying a gain of around 5.2% on a year-over-year basis.
HUM’s earnings beat the consensus estimate in three of the trailing four quarters and missed once, with the average surprise being 9.6%.
Humana Inc. Price and EPS Surprise
Humana Inc. price-eps-surprise | Humana Inc. Quote
Q3 Earnings Whispers for HUM
Our proven model predicts a likely earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is precisely the case here.
Humana has an Earnings ESP of +4.29% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
What’s Shaping HUM’s Q3 Results?
The Zacks Consensus Estimate for HUM’s third-quarter premiums indicates an 8.6% increase from the prior-year quarter’s reported figure, whereas our model predicts 8.2% growth. We expect total Medicare to witness nearly 6% growth in the quarter under review. Similarly, the consensus mark for service revenues signals a 25.6% increase from a year ago. These are expected to have positioned the company for an earnings beat in the third quarter.
However, the Zacks Consensus Estimate for operating income from the Insurance unit indicates a 1.9% decline from a year ago. The same for the CenterWell unit predicts a 2% decrease from the year-ago level.
Furthermore, the consensus estimate indicates that Humana’s investment income will see a 21% drop from the year-ago level. We expect total operating costs to increase 8.7% in the third quarter, pushing the figure above $31 billion. This is likely to have led to a year-over-year decline in the bottom line.
The consensus mark for the overall benefits expense ratio is pegged at 90.86% for the to-be-reported quarter, deteriorating from 89.9% a year ago. Also, the Zacks Consensus Estimate for insurance membership suggests a 7.1% year-over-year decline, whereas specialty membership is expected to grow 1.3%.
How Did Peers Perform?
Several healthcare companies, including Centene Corporation (CNC - Free Report) , Molina Healthcare, Inc. (MOH - Free Report) and Elevance Health, Inc. (ELV - Free Report) , have already reported their financial results for the September quarter of 2025. Here’s how they had performed:
Centene reported third-quarter 2025 adjusted earnings per share of 50 cents, which beat the Zacks Consensus Estimate of a loss of 21 cents. However, the bottom line fell from the year-ago profit of $1.62 per share.The results benefited from solid premium growth, fueled by expanding membership in the PDP and Commercial Marketplace businesses, along with overall growth in the Marketplace business. However, the upside was partly offset by Centene’s rising medical costs, declining service revenues and year-over-year membership falls in Medicaid and Medicare businesses.
Molina reported third-quarter 2025 adjusted EPS of $1.84, which missed the Zacks Consensus Estimate of $3.97. Also, the bottom line fell 69.4% from the year-ago period.The earnings were affected by higher medical care costs and general and administrative expenses. However, Molina’s rising premiums and rate hikes partially offset the negatives.
Elevance reported third-quarter 2025 adjusted EPS of $6.03, which surpassed the Zacks Consensus Estimate by 21.1%. Yet, the bottom line dropped 29.9% year over year. The results benefited from the back of strong growth in premiums, product revenues and net investment income. However, the upside was partly offset by a decline in Elevance’s overall medical membership due to Medicaid reverifications and an elevated expense level.